Published in final edited form as:

Tetrahedron Lett. 2012 December 5; 53(49): 6638–6640. doi:10.1016/j.tetlet.2012.09.035.

Ruthenium-Catalyzed Olefin Metathesis after Tetra-*n*-butylammonium Fluoride-Mediated Desilylation

Sami Osman and Kazunori Koide

Department of Chemistry, University of Pittsburgh, 219 Parkman Avenue, Pittsburgh, Pennsylvania 15260

Kazunori Koide: koide@pitt.edu

Abstract

One-pot procedures expedite organic synthesis but pose challenges in that many reagents must be compatible with each other. We discovered that the presence of $^n\text{Bu}_4\text{NF}$ hindered rutheniumcatalyzed olefin metathesis when $^n\text{Bu}_4\text{NF}$ -mediated desilylation and olefin metathesis were performed in one pot. This problem could be solved by the addition of $(\text{TMS})_2\text{O}$ to remove fluoride anions in order to facilitate the ruthenium-catalyzed olefin metathesis.

Keywords

metathesis; ruthenium; fluoride; silicon; one-pot

Small molecule inhibitors of pre-mRNA splicing are an emerging class of molecules that can be used as chemical probes and drug candidates.^{1–9} Direct inhibitors of the spliceosome known to date are pladienolides,^{4,10–12} herboxidiene,^{13–15} and FR901464^{2,16–18} and its analogs.^{3,19,20} While many of these splicing inhibitors are widely used in biochemical studies,^{1–5,21–23} their drug development lags behind. A pladienolide analog was advanced to phase I studies,⁶ but none of the FR901464 analogs advanced to the same level. In our laboratory, we reported an *in vivo* study of meayamycins; these FR901464 analogs, despite high potency *in vitro*, showed poor pharmacokinetics in mice.⁸ In order to design meayamycin analogs that are active *in vivo*, the absorption, distribution, metabolism, and excretion (ADME) of meayamycins must be elucidated.

A classic approach to the ADME studies of small molecules requires a highly sensitive method to detect the parent compound and its derivatives. The most common method is to label the parent compound with a radioisotope. However, organic synthesis of radioactive compounds imposes a challenge in that purification steps must be minimized.

Our previously reported synthetic scheme for meayamycin B is shown in Scheme 1a.^{19,20} Briefly, alkene **1** was subjected to oxymercuration-reduction conditions to form tetrahydrofuran **4** in 76% yield. The subsequent deprotection of the triethylsilyl (TES) group using tetra-*n*-butylammonium fluoride (TBAF) provided alcohol **5** in 97% yield. Finally, the

© 2012 Elsevier Ltd. All rights reserved.

Correspondence to: Kazunori Koide, koide@pitt.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

cross-olefin metathesis of this alcohol with diene **6** in the presence of nitro-Grela reagent **Ru-1** yielded meayamycin B in 44% yield.

We reasoned that the replacement of the hydrogen atom in the conversion of **2** to **3** with tritium should allow us to incorporate the radioactive atom in **4** and eventually in meayamycin B. In order to develop a one-pot procedure for the conversion of alkene **1** to meayamycin B to minimize purification steps, the alkene was treated with $\text{Hg}(\text{OAc})_2$ and NaBH_4 (Scheme 1b). *para*-Nitrobenzaldehyde was added to the resulting mixture to trap excess hydride. Subsequently, TBAF was added to furnish alcohol **5** without complications. Finally, diene **6** and **Ru-1** were added in this order in the same flask; however, the final cross-coupling reaction did not take place.

This problem raised a question about whether the presence of any of the preexisting molecules could interfere with the final step. Previously, Caulton and coworkers reported that treatment of a ruthenium dimer $[\text{Ru}(\text{P}^i\text{Pr}_3)_2\text{HCl}]_2$ with Me_4NF yields $[\text{Ru}(\text{P}^i\text{Pr}_3)_2\text{HF}]_2$.²⁴ We hypothesized that fluoride ions from the use of TBAF in excess might interfere with the metathesis reaction through the possible displacement of chloride of **Ru-1** with fluoride. To test our hypothesis, we compared the ring closing metathesis of the model substrate **7**²⁵ in the presence of **Ru-1**. Indeed, the addition of TBAF reduced the yield of **8** from 78% (Table 1, entry 1) to 15% (entry 2), supporting our hypothesis. Previous investigation of the effects of halogens in the olefin metathesis suggested that the catalyst's activities decrease as the halogens are changed from Cl to Br to I, due to the increase in *trans* influence and size of halogens.²⁶ Based on these results we would expect that fluorine on the ruthenium-based catalyst would have an increase in catalyst's activity; however, this was not the case in our experiment. Meanwhile, recent theoretical investigations suggested that a σ -withdrawing group would decrease the catalyst's activity.²⁷ Since fluorine atoms are highly electronegative, our results are in agreement with this suggestion.

In order to couple alcohol **5** and diene **6** after the TBAF-promoted deprotection of the TES group in one pot, it became necessary to remove fluoride ions. To this end, we treated the mixture of TBAF and the model substrate **7** with ditrimethylsilyl ether $(\text{TMS})_2\text{O}$ ^{28–31} with the anticipation that the fluoride ions would be trapped as fluorotrimethylsilane (b.p. 16 °C), which can be readily removed due to its high volatility. As anticipated, the ring-closing metathesis proceeded to form cyclopentene **8** in quantitative yield (entry 3). With this protocol in hand, we were able to convert alkene **1** to meayamycin B in one pot by adding $(\text{TMS})_2\text{O}$ in the final step as determined by HPLC and ^1H NMR spectroscopic analyses (Scheme 1b and Figure 1).

In conclusion, we discovered that fluoride anions interfere with ruthenium-catalyzed olefin metathesis reactions. Subsequently, we developed a protocol to effect the ruthenium-catalyzed olefin cross-metathesis after TBAF was used in the same flask. This study allowed us to establish potential access to tritium-labeled meayamycin B with one purification step. The use of $(\text{TMS})_2\text{O}$ may find other applications in which olefin metathesis is carried out immediately after the use of TBAF.

Protocol to prepare meayamycin B from alcohol 1: Alcohol **1** (10 mg, 34 μmol) and THF (0.3 mL) were placed in a 10-mL round-bottomed flask. The flask was cooled to 0 °C, and $\text{Hg}(\text{OAc})_2$ (13 mg, 41 μmol) was added. The resulting solution was stirred under a nitrogen atmosphere and slowly warmed to 26 °C over 5 h. The mixture was then cooled to –78 °C, then NaBH_4 (1.3 mg, 34 μmol) and Et_3B (1.0 M in THF, 37 μL , 37 μmol) were added. The mixture was stirred while warming to –40 °C over 3.5 h, followed by the addition of *para*-nitrobenzaldehyde (51 mg, 340 μmol). After this step, all of the experiments were carried out in an air atmosphere. The mixture was warmed to 26 °C and stirred at the same

temperature for 2.5 h. The mixture was then cooled to 0 °C, and TBAF (1.0 M in THF, 60 μ L, 60 μ mol) was added at the same temperature, followed by warming to 26 °C over 4 h. Afterwards, (TMS)₂O (110 mg, 860 μ mol) was added, and the mixture was stirred at the same temperature for 11 h. The mixture was then treated with a pH 7 buffer (1.23 M potassium phosphate, 0.25 mL), a solution of diene **6** (5 mg, 10 μ mol) in 1,2-dichloroethane (0.1 mL), and **Ru-1** (4 mg, 6 μ mol). The mixture was stirred in a 45 °C oil bath for 27 h, then passed through a short plug of silica gel. The filtrate was concentrated *in vacuo*, and the resulting residue was initially purified by preparative TLC (80% EtOAc in hexanes), then preparative HPLC (absorption at 232 nm. Elution conditions: flow rate = 10.0 mL/min, gradient: 60→100% MeCN in water over 15 min, then 10 min with 100% MeCN. Column: Agilent Prep-C18 column 21.2 $\times$ 150 mm, 5 μ m. Retention time = 12.9 min) to furnish meayamycin B (1.2 mg, 21% yield).

Acknowledgments

This work was in part supported by the US National Institutes of Health (R01 CA120792). We thank Apeiron Catalysts and Boehringer-Ingelheim Pharmaceuticals for the gift of **Ru-1**. S.O. is a recipient of a Graduate Excellence Fellowship from the University of Pittsburgh.

References

1. Furumai R, Uchida K, Komi Y, Yoneyama M, Ishigami K, Watanabe H, Kojima S, Yoshida M. *Cancer Sci.* 2010; 101:2483. [PubMed: 20726856]
2. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, Watanabe H, Kitahara T, Yoshida T, Nakajima H, Tani T, Horinouchi S, Yoshida M. *Nat. Chem. Biol.* 2007; 3:576.
3. Albert BJ, McPherson PA, O'Brien K, Czaicki NL, Destefino V, Osman S, Li M, Day BW, Grabowski PJ, Moore MJ, Vogt A, Koide K. *Mol. Cancer Ther.* 2009; 8:2308. [PubMed: 19671752]
4. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, Ishihama Y, Iwata M, Mizui Y. *Nat. Chem. Biol.* 2007; 3:570. [PubMed: 17643112]
5. Yokoi A, Kotake Y, Takahashi K, Kadowaki T, Matsumoto Y, Minoshima Y, Sugi NH, Sagane K, Hamaguchi M, Iwata M, Mizui Y. *FEBS J.* 2011; 278:4870. [PubMed: 21981285]
6. Eskens FARFJ, Burger H, de Jonge MJ, Wanders J, Lopez-Anaya A, Baselga J, Taberno J. *J. Clin. Oncol.* 2009; 27:3508.
7. Lagisetty C, Pourpak A, Goronga T, Jiang Q, Cui X, Hyle J, Lahti JM, Morris SW, Webb T. R. J. *Med. Chem.* 2009; 52:6979. [PubMed: 19877647]
8. Osman S, Waud WR, Gorman GS, Day BW, Koide K. *Med. Chem. Commun.* 2011; 2:38.
9. Girard C, Will CL, Peng J, Makarov EM, Kastner B, Lemm I, Urlaub H, Hartmuth K, Luhrmann R. *Nat. Commun.* 2012; 3:994. [PubMed: 22871813]
10. Mizui Y, Sakai T, Iwata M, Uenaka T, Okamoto K, Shimizu H, Yamori T, Yoshimatsu K, Asada M. *J. Antibiot.* 2004; 57:188. [PubMed: 15152804]
11. Sakai T, Asai N, Okuda A, Kawamura N, Mizui Y. *J. Antibiot.* 2004; 57:180. [PubMed: 15152803]
12. Sakai T, Sameshima T, Matsufuji M, Kawamura N, Dobashi K, Mizui Y. *J. Antibiot.* 2004; 57:173. [PubMed: 15152802]
13. Isaac BG, Ayer SW, Elliott RC, Stonard R. J. *J. Org. Chem.* 1992; 57:7220.
14. Sakai YTT, Akiyama T, Yoshida T, Mizukami T, Akinaga S, Horinouchi S, Yoshida M, Yoshida T. *J. Antibiot.* 2002; 55:863. [PubMed: 12523819]
15. Hasegawa M, Miura T, Kuzuya K, Inoue A, Won Ki S, Horinouchi S, Yoshida T, Kunoh T, Koseki K, Mino K, Sasaki R, Yoshida M, Mizukami T. *ACS Chem. Biol.* 2011; 6:229. [PubMed: 21138297]
16. Nakajima H, Hori Y, Terano H, Okuhara M, Manda T, Matsumoto S, Shimomura K. *J. Antibiot.* 1996; 49:1204. [PubMed: 9031665]

17. Nakajima H, Sato B, Fujita T, Takase S, Terano H, Okuhara M. J. Antibiot. 1996; 49:1196. [PubMed: 9031664]
18. Nakajima H, Takase S, Terano H, Tanaka H. J. Antibiot. 1997; 50:96. [PubMed: 9066774]
19. Albert BJ, Sivaramakrishnan A, Naka T, Czaicki NL, Koide K. J. Am. Chem. Soc. 2007; 129:2648. [PubMed: 17279752]
20. Osman S, Albert BJ, Wang Y, Li M, Czaicki NL, Koide K. Chem.–Eur. J. 2011; 17:895. [PubMed: 21226105]
21. Roybal GA, Jurica M. S. Nucleic Acids Res. 2010; 38:6664. [PubMed: 20529876]
22. Corrionero A, Minana B, Valcarcel J. Genes Dev. 2011; 25:445. [PubMed: 21363963]
23. Visconte V, Makishima H, Jankowska A, Szpurka H, Traina F, Jerez A, O'Keefe C, Rogers HJ, Sekeres MA, Maciejewski JP, Tiu R. V. Leukemia. 2012; 26:542. [PubMed: 21886174]
24. Coalter JN III, Huffman JC, Streib WE, Caulton K. G. Inorg. Chem. 2000; 39:3757. [PubMed: 11196766]
25. Grela K, Harutyunyan S, Michrowska A. Angew. Chem. Int. Ed. 2002; 41:4038.
26. Dias EL, Nguyen ST, Grubbs RH. J. Am. Chem. Soc. 1997; 119:3887.
27. Occhipinti G, Bjørsvik H-R, Jensen VR. J. Am. Chem. Soc. 2006; 128:6952. [PubMed: 16719476]
28. Panne P, Naumann D, Hoge B. J. Fluorine Chem. 2001; 112:283.
29. Chatani N, Amishiro N, Murai S. J. Am. Chem. Soc. 1991; 113:7778.
30. Vicente J, Gil-Rubio J, Bautista D. Inorg. Chem. 2001; 40:2636. [PubMed: 11375671]
31. Taw FL, Scott BL, Kiplinger JL. J. Am. Chem. Soc. 2003; 125:14712. [PubMed: 14640639]

Figure 1.
 ^1H NMR spectrum of meayamycin B from the one-pot protocol (top) and authentic meayamycin B (bottom).

Scheme 1.

(a) Original protocol to prepare meayamycin B. (b) Preparation of meayamycin B from **1** using the one-pot procedure.

Table 1

Ring closing metathesis of the model substrate **7**.

Entry	Additives		Yield ^a
	TBAF (equiv)	(TMS) ₂ O (equiv)	
1	0	0	78% ^b
2	1	0	15% ^c
3	1	1.2	quant.

^aYields were determined by ¹H NMR spectroscopic analysis of the reaction mixture that contained PhCHO as an internal standard.

^bYield taken from reference 25.

^c**7** was the remaining 85%.